var data={"title":"Palonosetron: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Palonosetron: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6716?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=palonosetron-drug-information\" class=\"drug drug_general\">see &quot;Palonosetron: Drug information&quot;</a> and <a href=\"topic.htm?path=palonosetron-patient-drug-information\" class=\"drug drug_patient\">see &quot;Palonosetron: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14877561\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aloxi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50297423\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aloxi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060801\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">5-HT<sub>3</sub> Receptor Antagonist</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiemetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060794\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=palonosetron-drug-information\" class=\"drug drug_general\">see &quot;Palonosetron: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note: </b> Dosing presented in both mcg and mg; use extra caution to verify correct units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting; prevention:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents &lt;17 years: 20 <b>mcg</b>/kg as a single dose; maximum dose: 1500 <b>mcg</b>/dose (1.5 mg/dose); beginning ~30 minutes prior to the start of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;17 years: 0.25 mg as a single dose administered ~30 minutes before chemotherapy </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Fixed dosing: Limited data available: Children and Adolescents 2 to 15 years: 0.25 mg single dose beginning ~30 minutes prior to the start of chemotherapy; dosing based on a randomized comparison trial with ondansetron which evaluated 100 chemotherapy courses in each arm and showed a statistically significant reduction in emetic events on days 0 to 3 in the palonosetron group and clinically significant reduction in emetic events on days 4 to 7 (up to 6 emetic events in the ondansetron group vs none with palonosetron) (Sep&uacute;lveda-Vild&oacute;sola, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative nausea and vomiting (PONV); prevention:</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &lt; 17 years: Limited data available; efficacy results variable: 1 <b>mcg</b>/kg as a single dose; maximum dose: 75 <b>mcg</b>/dose (0.075 mg/dose) immediately prior to anesthesia induction; dosing based on a double-blind randomized comparative trial with ondansetron which showed complete response in 78.2% of the palonsetron group and 82.7% of the ondansetron; however, palonsetron efficacy data did not meet noninferiority margin; safety analysis showed no unexpected adverse effects, similar data as adult patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years: Limited data available in 17 years of age: 0.075 mg immediately prior to anesthesia induction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Chemotherapy-induced nausea and vomiting; prevention:</b> IV: 0.25 mg as a single dose administered ~30 minutes prior to the start of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Postoperative nausea and vomiting; prevention (PONV):</b> IV: 0.075 mg immediately prior to anesthesia induction </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults: No adjustment is necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: No adjustment is necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205824\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aloxi: 0.25 mg/5 mL (5 mL) [contains edetate disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205812\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060804\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Flush IV line with NS prior to and following administration</p>\n    <p style=\"text-indent:0em;\">Prevention of chemotherapy-induced nausea and vomiting: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: May administer IV undiluted or further dilute (Trissel 2004a) and infuse over 15 minutes, beginning ~30 minutes prior to the start of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;17 years and Adults: Administer IV undiluted, infuse over 30 seconds, beginning ~30 minutes prior to the start of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of postoperative nausea and vomiting: May administer IV undiluted and infuse over 10 seconds immediately prior to anesthesia induction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205838\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not freeze. Protect from light. Solutions of 5 mcg/mL and 30 mcg/mL in NS, D5W, D5<sup>1</sup>/<sub>2</sub>NS, and D5LR injection are stable for 48 hours at room temperature and 14 days under refrigeration (Trissel 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules [Canadian product]: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060803\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with initial and repeat courses of emetogenic chemotherapy (including highly emetogenic) (FDA approved in ages &ge;1 month and adults); prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205868\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aloxi may be confused with Eloxatin, oxaliplatin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Palonosetron may be confused with dolasetron, granisetron, ondansetron</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205866\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events reported for adults unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Bradycardia (chemotherapy-associated), prolonged Q-T interval on ECG (more common in PONV), sinus bradycardia (PONV), tachycardia (may be nonsustained), hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety (chemotherapy-associated), dizziness (infants, children, adolescents, and adults), headache (chemotherapy-associated; more common in adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus (PONV) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyperkalemia (chemotherapy-associated) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Constipation (chemotherapy-associated), diarrhea, flatulence </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT (may be transient), increased serum AST (may be transient) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (chemotherapy-associated) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Amblyopia, anasarca, anemia, anorexia, arthralgia, chills, decreased appetite, decreased blood pressure, decreased gastrointestinal motility, decreased platelet count, dermatological disease (infants, children, and adolescents), distended vein, drowsiness, dyskinesia (infants, children, and adolescents), dyspepsia, epistaxis, erythema, euphoria, extrasystoles, eye irritation, flattened T wave on ECG, flu-like symptoms, hiccups, hot flash, hyperglycemia, hypersensitivity (very rare), hypertension, hypokalemia, hypoventilation, increased bilirubin (transient), increased liver enzymes, infusion site pain (infants, children, and adolescents), injection site reaction (very rare; includes burning sensation at injection site, discomfort at injection site, induration at injection site, pain at injection site), insomnia, ischemic heart disease, limb pain, metabolic acidosis, motion sickness, paresthesia, serotonin syndrome, sialorrhea, sinus arrhythmia, sinus tachycardia, supraventricular extrasystole, tinnitus, vein discoloration, ventricular premature contractions  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205829\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to palonosetron or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205815\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ECG effects: Selective 5-HT<sub>3</sub> receptor antagonists have been associated with dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QTc, JT). A thorough QT/QTc study evaluating the effect of palonosetron on QT/QTc demonstrated a magnitude of effect less than the threshold for regulatory concern (Morganroth 2016). Reduction in heart rate may occur with the 5-HT<sub>3</sub> antagonists, including palonosetron (Gonullu 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity (including anaphylaxis) has been reported in patients with or without known hypersensitivity to other 5-HT<sub>3</sub> receptor antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Serotonin syndrome has been reported with 5-HT<sub>3</sub> receptor antagonists, predominantly when used in combination with other serotonergic agents (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, and/or methylene blue). Some of the cases have been fatal. The majority of serotonin syndrome reports due to 5-HT<sub>3</sub> receptor antagonists have occurred in a post-anesthesia setting or in an infusion center. Serotonin syndrome has also been reported following overdose of another 5-HT<sub>3</sub> receptor antagonist. Monitor patients for signs of serotonin syndrome, including mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis, dizziness, flushing, hyperthermia); neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination); gastrointestinal symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. If serotonin syndrome occurs, discontinue 5-HT<sub>3</sub> receptor antagonist treatment and begin supportive management.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chemotherapy-associated emesis: Antiemetics are most effective when used prophylactically (Roila 2016). If emesis occurs despite optimal antiemetic prophylaxis, re-evaluate emetic risk, disease, concurrent morbidities and medications to assure antiemetic regimen is optimized (Hesketh 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Postoperative nausea and vomiting: Use is not recommended if there is little expectation of postoperative nausea and vomiting (PONV); may use for low expectation of PONV if it is essential to avoid nausea and vomiting in the postoperative period.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205854\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205819\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12965&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Antiemetics (5HT3 Antagonists) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205821\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205831\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Use during pregnancy only if clearly needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060800\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity reactions; emesis episodes; HR</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205814\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Palonosetron is a selective 5-HT<sub>3</sub> receptor antagonist, blocking serotonin, both on vagal nerve terminals in the periphery and centrally in the chemoreceptor trigger zone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205828\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Capsules [Canadian product]: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 month to 17 years: Mean range: 5.3 to 6.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 8.3 &plusmn; 2.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~62%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: ~50% metabolized via CYP enzymes (and likely other pathways) to relatively inactive metabolites (N-oxide-palonosetron and 6-S-hydroxy-palonosetron); CYP1A2, 2D6, and 3A4 contribute to its metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Capsules [Canadian product]: 97%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: Children 1 month to 17 years: Median: 29.5 hours (range: 20 to 30 hours); Adults: ~40 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak (plasma): Capsules [Canadian product]: 5.1 &plusmn; 5.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80%; 40% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and children &lt;2 years: 0.31 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;12 years: Mean range: 0.19 to 0.23 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years, Adolescents, and Adults: 0.16 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5062442\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aloxi Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/5 mL (5 mL): $543.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539911\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aloxi (AT, AU, BB, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IS, IT, JP, KR, LT, LU, LV, MT, MY, NL, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, TH, TR, TW, VN);</li>\n      <li>Avonil (BD);</li>\n      <li>Lowvo (CN);</li>\n      <li>Onicit (AR, BR, CL, CO, CR, DO, EC, GT, HN, MX, NI, PA, PE, SV, VE);</li>\n      <li>Palnox (BD);</li>\n      <li>Palorex (BD);</li>\n      <li>Paloxi (BD, ID, IL, KR);</li>\n      <li>Paloxiron (BD);</li>\n      <li>Palzen (IN);</li>\n      <li>Zhiruo (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aloxi (palonosetron) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; May 2014. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gonullu G, Demircan S, Demirag MK, et al. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer. 2012;20(7):1435-1439. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/21773677/pubmed\" target=\"_blank\" id=\"21773677\">21773677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gralla R, Lichinitser M, Van Der Vegt S, et al, &ldquo;Palonosetron Improves Prevention of Chemotherapy-Induced Nausea and Vomiting Following Moderately Emetogenic Chemotherapy: Results of a Double-Blind Randomized Phase III Trial Comparing Single Doses of Palonosetron With Ondansetron,&rdquo; <i>Ann Oncol</i>, 2003, 14(10):1570-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/14504060/pubmed\" target=\"_blank\" id=\"14504060\">14504060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kupie TC, Trusley C, Ben M, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated y-site administration. Am J Health-Syst Pharm, 2008, 65(18):1735-1739. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/18769000/pubmed\" target=\"_blank\" id=\"18769000\">18769000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morganroth L, Parisi S, Spinelli T, et al. High dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double-blind, randomized, parallel E14 study of palonosetron vs. moxifloxacin or placebo. Presented at the 14th European Conference of Clinical Oncology (ECCO), September 2007; Barcelona, Spain.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia Consensus Conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sep&uacute;lveda-Vild&oacute;sola AC, Betanzos-Cabrera Y, Lastiri GG, et al, &quot;Palonosetron Hydrochloride Is an Effective and Safe Option to Prevent Chemotherapy-Induced Nausea and Vomiting in Children,&quot; <i>Arch Med Res</i>, 2008, 39(6):601-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/18662592/pubmed\" target=\"_blank\" id=\"18662592\">18662592</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siddiqui MA and Scott LJ, &ldquo;Palonosetron,&rdquo; <i>Drugs</i>, 2004, 64(10):1125-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/15139789/pubmed\" target=\"_blank\" id=\"15139789\">15139789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, Trusley C, Ben M, Kupiec TC. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated y-site administration. Am J Health-Syst Pharm, 2007, 64 (11):1209-1213.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/17519464/pubmed\" target=\"_blank\" id=\"17519464\">17519464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, Xu QA. &quot;Physical and Chemical Stability of Palonosetron HCl in 4 Infusion Solutions,&quot; <i>Ann Pharmacother</i>, 2004a, 38(10):1608-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/15328393/pubmed\" target=\"_blank\" id=\"15328393\">15328393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, Zhang Y. Compatibility and stability of aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. Intl J Pharm Compounding, 2004b, 8(5):398-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/23924770/pubmed\" target=\"_blank\" id=\"23924770\">23924770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated y-site administration. <i>Ann Pharmacother</i>, 2005, 39(2):280-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/15613463/pubmed\" target=\"_blank\" id=\"15613463\">15613463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      WHO Pharmaceuticals Newsletter. Ondansetron and serotonin syndrome. 2012; 3:16-21.\n    </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xu QA, Trissel LA. Compatibility of palonosetron with cyclophosphamide and with ifosfamide during simulated y-site administration. Am J Health Syst Pharm, 2005, 62(19):1998-2000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-pediatric-drug-information/abstract-text/16174835/pubmed\" target=\"_blank\" id=\"16174835\">16174835</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12965 Version 94.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F14877561\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50297423\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060801\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060794\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F205824\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F205812\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060804\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F205838\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060803\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F205868\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F205866\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F205829\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F205815\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F205854\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F205819\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F205821\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F205831\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060800\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F205814\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F205828\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5062442\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539911\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12965|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=palonosetron-drug-information\" class=\"drug drug_general\">Palonosetron: Drug information</a></li><li><a href=\"topic.htm?path=palonosetron-patient-drug-information\" class=\"drug drug_patient\">Palonosetron: Patient drug information</a></li></ul></div></div>","javascript":null}